目的 觀察馬來酸麥角新堿注射液聯(lián)合縮宮素注射液預防宮縮乏力性產(chǎn)后出血的臨床療效。方法 選取2019年1月-2019年3月就診于湘鄉(xiāng)市人民醫(yī)院分娩的產(chǎn)婦586例作為研究對象，按照用藥情況分為觀察組（295例）和對照組（291例）。對照組在胎兒娩出后使用縮宮素注射液，陰道分娩產(chǎn)婦肌肉注射10 IU，剖宮產(chǎn)宮體注射20 IU后；另取縮宮素10 IU加入500 mL葡萄糖溶液中緩慢靜滴。觀察組在對照組用藥基礎上使用馬來酸麥角新堿注射液，即胎兒娩出后，陰道分娩產(chǎn)婦肌肉注射10 IU縮宮素和0.2 mg麥角新堿，剖宮產(chǎn)宮體注射20 IU縮宮素和0.2 mg麥角新堿后；另取縮宮素10 IU加入500 mL葡萄糖溶液緩慢靜滴。觀察兩組患者產(chǎn)后2 h、24 h出血量及產(chǎn)后出血發(fā)生率，比較兩組額外止血措施的使用情況及不良反應。結果 治療后，對照組產(chǎn)后出血發(fā)生率為13.4%，觀察組為2.7%，兩組比較差異有統(tǒng)計學意義（P<0.05）。治療后，觀察組產(chǎn)后2 h、產(chǎn)后24 h出血量均明顯少于對照組，差異具有統(tǒng)計學意義（P<0.05）。治療后，觀察組額外使用宮縮劑的比例為8.5%，顯著低于對照組的19.2%，差異具有統(tǒng)計學意義（P<0.05）。治療期間，觀察組惡心的發(fā)生率為18.0%，高于對照組的13.1%，兩組比較差異有統(tǒng)計學意義（P<0.05）。結論 馬來酸麥角新堿聯(lián)合縮宮素對于預防宮縮乏力性產(chǎn)后出血效果顯著，且安全性良好。

Objective To observe the clinical effect of Ergometrine Maleate Injection combined with Oxytocin Injection on the prevention of postpartum hemorrhage caused by uterine atony. Methods A total of 586 cases of puerpera in the Xiangxiang People's Hospital from January 2019 to March 2019 were selected as the research object, and were divided into observation group (295 cases) and control group (291 cases) according to the medication situation. Puerpera in the control group were given Oxytocin Injection after the delivery, 10 IU was intramuscularly injected to the parturient of vagina delivery, and 20 IU was injected to the cesarean section body; and 10 IU of Oxytocin Injection was added to 500 mL glucose solution for slow intravenous drip. Puerpera in the observation group were treated with Ergometrine Maleate Injection on the basis of the control group, after the delivery, 10 IU Oxytocin Injection and 0.2 mg Ergometrine Maleate Injection were intramuscularly injected to the parturient of vagina delivery, 20 IU Oxytocin Injection and 0.2 mg Ergometrine Maleate Injection were injected to the cesarean section body; and 10 IU of Oxytocin Injection was added to 500 mL glucose solution for slow intravenous drip. The amount of bleeding and the incidence of postpartum bleeding were observed at 2 and 24 h after delivery, and the use of additional hemostasis measures and adverse reactions were compared between two groups. Results After treatment, the incidence of postpartum hemorrhage was 13.4% in the control group, and 2.7% in the observation group, the difference was statistically significant (P<0.05). After treatment, the amount of bleeding in the observation group was significantly less than that in the control group (P<0.05). After the treatment, the proportion of extra use of uterine contractions in the observation group was 8.5%, significantly lower than 19.2% in the control group, the difference was statistically significant (P<0.05). During the treatment, the incidence of nausea in the observation group was 18.0%, which was higher than 13.1% in the control group, the difference between the two groups was statistically significant (P<0.05). Conclusion Ergometrine Maleate Injection combined with Oxytocin Injection is effective and safe in the prevention of postpartum hemorrhage due to uterine atony.

R984